^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
270P - Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
Published date:
09/14/2020
Excerpt:
...the addition of apatinib to TP neoadjuvant chemotherapy (Apa+TP) significantly increased the pCR rate (73.9%, 17/23) in patients with stage IIb-IIIc triple-negative and HER2-positive breast cancer (P=0.026).
Secondary therapy:
carboplatin + albumin-bound paclitaxel; D19466 + paclitaxel liposomal; carboplatin + paclitaxel liposomal; albumin-bound paclitaxel + D19466; cisplatin + docetaxel; carboplatin + docetaxel; docetaxel + D19466; cisplatin + albumin-bound paclitaxel; cisplatin + paclitaxel liposomal
Trial ID:
Source:
Title:
Apatinib combined with trastuzumab and albumin‑bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti‑HER2 TKIs: A case report
Published date:
12/20/2022
Excerpt:
The present study reported on a case of a pretreated patient with HER2‑positive advanced breast cancer with brain metastases who developed resistance to multiple lines of HER2‑targeted treatment. The patient was treated with apatinib combined with trastuzumab and albumin‑bound paclitaxel. The patient achieved partial response to the third‑line treatment with a progression‑free survival of 9 months.
Secondary therapy:
albumin-bound paclitaxel
DOI:
10.3892/ol.2022.13642
